Recursion Pharmaceuticals, Inc. (RXRX)
NasdaqGS · Price as of · Nasdaq Real Time Price
- Analysts6
- Implied upside+106.2%
- Target range$4.00 to $10.00
- EPS expected-$0.23
- A year ago-$0.36
- Revenue expected$14.2M +175%
- Estimate range-$0.25 to -$0.20
SEC filings
| Form | Filed | Description |
|---|---|---|
| 144 | August 21, 2026 | View on EDGAR |
| 144 | August 20, 2026 | View on EDGAR |
| 144 | August 19, 2026 | View on EDGAR |
| 4 | August 18, 2026 | FORM 4 |
| 4 | August 18, 2026 | FORM 4 |
| 4 | August 18, 2026 | FORM 4 |
| 144 | August 18, 2026 | View on EDGAR |
| 144 | August 13, 2026 | View on EDGAR |
Frequently asked questions
When does RXRX report earnings?
Recursion Pharmaceuticals, Inc. (RXRX) is scheduled to report quarterly results on November 4, 2026 (estimated). The 6-analyst consensus is -$0.23 per share on revenue of $14.2M for the quarter ending September 30, 2026, against -$0.36 and $5.2M a year earlier. It has beaten the consensus EPS estimate in 3 of the last four quarters. The date is an estimate from past reporting patterns and can move until the company confirms it.
What do analysts expect for RXRX?
6 analysts cover Recursion Pharmaceuticals, Inc. (RXRX). The consensus rating is Buy. The average price target is $7.22, in a range of $4.00 to $10.00.
Are insiders buying or selling RXRX?
We have no qualifying Form 4 insider purchases or sales on record for Recursion Pharmaceuticals, Inc. (RXRX). Sales are only tracked above a dollar threshold, so small routine trades may not appear.
Where can I see RXRX SEC filings?
Recent filings are listed on this page, newest first. The latest is a 144 filed August 21, 2026.